---
title: Hepatymo
image: "/uploads/06-hepatymo.jpg"
group: Hepatitis B
ingredient: Tenofovir disoproxil fumarat 300 mg
excipients: Excipients 1 capsule
assign: |-
  - Super-chronic hepatitis B in adults with compensated liver disease and evidence of viral replication and histological evidence of active inflammation or fibrosis.
  - Combination with other antiretroviral drugs in the treatment of HIV.
expiry_date: 36 months
pack: Box of 3 blisters x 10 film-coated tablets.
preservation: Store in a dry place, at a temperature not exceeding 30Â°C, protected
  from light.
origin: Vietnam
amount_use: |-
  HIV infection: 1 tablet x 1 time/day, in combination with other antiretroviral drugs.
  Occupational HIV post-exposure prophylaxis (preferably within a few hours & continued for the next 4 weeks if tolerated): 1 tablet x 1 time/day, in combination with other antiretroviral drugs ( lamivudine or emtricitabine).
  Non-occupational HIV post-exposure prophylaxis (preferably within 72 hours & continued for 28 days): 1 tablet x 1 time/day, in combination with at least 2 other antiretroviral agents.
contraindications: Patients who are sensitive to the components of the drug.
careful: |-
  Monitor serum ALT & HBV DNA levels after treatment discontinuation.
  Discontinue treatment if the patient develops lactic acidosis, severe hepatomegaly with steatosis, and after treatment for severe hepatitis.
  Should not be used in patients with galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption.
  Elderly, patients at risk of renal dysfunction, cirrhosis, HIV and hepatitis B co-infection, lipid metabolism disorders, skeletal abnormalities, history of joint pain and stiffness, difficulty in movement.

---
